Han-Kang KY Secures Strategic Investment from OrbiMed, to List on Innovation Board on the 29th
NQ Score
51/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Han-Kang KY has set its IPO price at NT$120 per share and will list on the Innovation Board on the 29th. Global healthcare fund OrbiMed has joined as a strategic investor. The company has raised approximately NT$4.5 billion to fund clinical trials and global expansion.
AI Analysis
Frequently Asked Questions
- Q: What is the business of Han-Kang KY?
- A: It is a biopharmaceutical company focused on drug development.